维得利珠单抗(Vedolizumab) - 药物靶点：α4β7_在研适应症：回肠疾病，活动性中度克罗恩病，活动性重度克罗恩病_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Kynteles、Vedolizumab (Genetical Recombination)、Vedolizumab (genetical recombination) (JAN)

+ [16]

靶点

α4β7

作用方式

拮抗剂

作用机制

α4β7拮抗剂(整合素α-4/β-7复合体拮抗剂)

治疗领域

免疫系统疾病消化系统疾病其他疾病+ [2]

在研适应症

回肠疾病活动性中度克罗恩病活动性重度克罗恩病+ [9]

非在研适应症

急性移植物抗宿主病乳糜泻原发性硬化性胆管炎+ [8]

原研机构

Millennium Pharmaceuticals, Inc.

在研机构

Takeda Pharmaceutical Co., Ltd.Takeda Development Center Americas, Inc.Takeda Pharma AS

+ [9]

非在研机构

Millennium Pharmaceuticals, Inc.

权益机构

Royalty Pharma PlcThe General Hospital Corp.

最高研发阶段批准上市

首次获批日期

美国 (2014-05-20),

溃疡性结肠炎克罗恩病

最高研发阶段(中国)批准上市

特殊审评临床急需境外新药 (中国)、孤儿药 (澳大利亚)、快速通道 (美国)

登录后查看时间轴

结构/序列

Sequence Code 9976148H

来源: *****

Sequence Code 13007748L

来源: *****

关联

165

项与维得利珠单抗相关的临床试验

CTIS2024-514964-24-00

/ Not yet recruiting临床3期IIT

FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial

开始日期2026-06-01

申办/合作机构-

ChiCTR2600120506

/ Not yet recruitingN/AIIT

A multicentre randomised controlled study to evaluate the efficacy of bladder-preserving therapy with oral probiotics combined with PD-1 monoclonal antibody and Disitamab Vedotin in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) and low serum butyrate

开始日期2026-03-20

申办/合作机构

中山大学孙逸仙纪念医院

[+1]

DRKS00038753

/ SuspendedN/A

A Clinical Decision Support Tool (CDST) for Vedolizumab (VDZ) in Patients with Crohn’s Disease – a German Chart Review - VDZ-CDST German Chart Review

开始日期2026-03-06

申办/合作机构

Takeda GmbH

100 项与维得利珠单抗相关的临床结果

登录后查看更多信息

100 项与维得利珠单抗相关的转化医学

登录后查看更多信息

100 项与维得利珠单抗相关的专利（医药）

登录后查看更多信息

1,985

项与维得利珠单抗相关的文献（医药）

2026-04-01·Current Opinion in Critical Care

Update on intestinal transplantation for the intensivist

Review

作者: Al-Khafaji, Ali ; Kim, Hyung Kook

Purpose of review:

This article provides an overview of intestinal transplantation, focusing on perioperative management and the recognition and treatment of complications in the intensive care unit. The review aims to update intensivists with a comprehensive understanding of the care of intestinal transplant recipients.

Recent findings:

Despite advances in immunosuppression, donor graft preparation, perioperative care, and the management of complications such as rejection, graft-versus-host disease, and infection, graft and patient survival rates following intestinal transplantation have not improved over the past decade and remain inferior to those of other solid organ transplants. Although surgical techniques have largely remained unchanged, some transplant centers have reported performing intestinal transplantation without a stoma and utilizing preoperative embolization in selected cases.Recent updates in maintenance immunosuppression include the expanded use of less commonly employed agents as part of multimodal regimens such as mammalian target of rapamycin inhibitors and antimetabolites as well as the introduction of therapies not traditionally used for maintenance, including costimulatory blockade, interleukin-2 receptor blockade, and vedolizumab.

Summary:

In recipients of intestinal transplants, prompt identification of infections and complications such as rejection, posttransplant lymphoproliferative disorder, and graft-versus-host disease is essential. Early recognition and intervention are critical to preserving graft function and improving overall survival. Effective management of these perioperative challenges requires a multidisciplinary team approach, with intensivists playing a central role in achieving optimal outcomes.

2026-04-01·DEN open

Vedolizumab Induces Remission in Two Cases of Ulcerative Colitis With Upper Gastrointestinal Involvement

Article

作者: Otoyama, Yumi ; Yoshida, Hitoshi ; Katagiri, Atsushi ; Higuchi, Kensuke ; Suzuki, Norihiro ; Nakatani, Shinya ; Ohara, Jyun ; Fujiwara, Takahisa ; Kikuchi, Kazuo ; Yamazaki, Yuta

ABSTRACT:

Ulcerative colitis (UC) predominantly affects the colon; upper gastrointestinal involvement (UGI) has been reported, but no established treatments exist. We report two cases of UC with concomitant UGI that showed positive responses to vedolizumab therapy. Case 1 involved a 29‐year‐old man who developed continuous inflammation extending from the stomach to the jejunum 1 month after an initial UC diagnosis. Intravenous prednisolone provided clinical remission; however, maintenance therapy with oral azathioprine was unsuccessful. Vedolizumab was initiated. Three months later, esophagogastroduodenoscopy (EGD) and colonoscopy confirmed the resolution of inflammation. Case 2 involved a 19‐year‐old man diagnosed with UGI via endoscopy while being evaluated for nausea and fever during UC treatment. 5‐aminosalicylic acid and prednisolone therapies were ineffective; therefore, vedolizumab was administered. Three months later, EGD confirmed mucosal healing. Both patients have maintained clinical remission for >2 years. To our knowledge, this is the first report of UC with UGI involvement that was successfully treated with vedolizumab. These findings suggest that vedolizumab is effective and safe for UGI treatment.

2026-03-04·SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Liver enzyme alterations during pregnancy in IBD are not attributable to disease activity or medication

Article

作者: van Dop, Willemijn A. ; Prins, Jelmer R. ; Donker, Hylke C. ; Visschedijk, Marijn C. ; Tauber, Tjebbe ; Dijkstra, Gerard ; van Es, Bram ; van der Woude, C. Janneke ; Bouwknegt, Dianne G.

BACKGROUND:

Inflammatory bowel disease (IBD) is often diagnosed during reproductive age, requiring adequate management during pregnancy. Physiological changes during pregnancy affect liver enzymes, complicating interpretation in a population prone to liver test abnormalities. This study aims to investigate liver enzyme trends throughout pregnancy in women with IBD.

METHODS:

A retrospective cohort study was conducted in three Dutch university hospitals. Pregnant women with IBD were included; liver enzyme levels were analyzed throughout pregnancy using Bayesian modeling. The association between liver enzymes and IBD disease activity, medication, pregnancy and adverse pregnancy outcomes was assessed, with estimated marginal means (EMMs) reported across trimesters and clinical subgroups.

RESULTS:

Liver enzyme levels exhibited significant trimester-specific variations in pregnant individuals with IBD. Levels of aminotransferases, γ-glutamyl transferase (γGT) and bilirubin generally declined, particularly in the second trimester, whereas alkaline phosphatase (ALP) levels increased markedly in the third trimester, mirroring physiological changes observed in healthy pregnancies. Adverse pregnancy outcomes were not associated with differences in liver enzyme levels. Several medications - particularly ustekinumab, vedolizumab, thiopurines, corticosteroids and amino salicylates - were associated with liver enzyme values or interacted with pregnancy, modulating the direction or magnitude of change. However, these effects were generally modest and remained within reference values.

CONCLUSIONS:

In pregnant women with IBD, changes in liver enzyme levels reflect physiological gestational adaptations rather than pharmacologic effects. Although medication-specific interactions were detected, their clinical significance appears limited. Marked elevations in liver enzymes during pregnancy cannot routinely be attributed to IBD activity or medication and warrant urgent analysis.

601

项与维得利珠单抗相关的新闻（医药）

2026-04-08

·成都天府国际生物城

Town主·探秘 | 康诺亚：自免Biopharma的进阶之路

近日，生物城企业康诺亚公布了2025年全年业绩，一组组亮眼的数据瞬间点燃了行业关注的目光。财报显示 2025年康诺亚实现总收入7.2亿元，同比增长67%；其中核心产品收入达3.1亿元，即便在未进医保的首个完整商业化年度，依然展现出极强的市场韧性。这不仅是一家企业的成绩单，更是生物城在创新药研发、商业化落地、全球化BD全链条生态培育下的 “高光时刻”。当国产创新药普遍面临出海阵痛康诺亚为何能在全球竞争红海中硬刚巨头今天就跟Town主一起来一探究竟硬刚全球药王本土产品实现 “弯道超车” 在竞争极度白热化的自免赛道上，康诺亚的核心单品司普奇拜单抗无疑是一匹“黑马”。司普奇拜单抗之所以能出奇制胜，源于康诺亚差异化洞察国内鼻科适应症巨大未满足临床需求；抗凭借皮肤科 + 鼻科的精准双线布局，2026年特应性皮炎（AD）、慢性鼻窦炎伴鼻息肉（CRSwNP）、季节性过敏性鼻炎（SAR）三大适应症均纳入医保，其中SAR是独家适应症。鼻炎（AR）是中国特色大市场，尽管CRSwNP不属于AR但两者经常合并存在（约40%的CRSwNP患者同时患有AR），2021年数据显示中国有2000万患者，现有治疗方式包括手术（易复发）、全身皮质类固醇（有概率带有严重全身副作用），有效生物制剂急需补位；AR是更庞大的市场，中国AR患者约2亿–2.5亿，其中SAR约占20%。据调查显示，即使规律使用鼻用糖皮质激素/抗组胺等一线用药，仍有50%-60%中重度患者症状难以控制，存在升级治疗需求。除了作为独家产品填补未满足临床空缺，过硬的产品力有望推动司普奇拜单抗成为鼻科重量级单品。更值得骄傲的是，这款来自生物城的创新药，两项关键临床研究分别登顶国际顶刊JAMA、Nature Medicine，成为中国鼻科创新药首次登顶JAMA的历史性时刻，彰显了在全球自免领域的临床研究硬实力。临床空白+独家产品，顶刊认证起效快、疗效&安全性好，叠加司普奇拜单抗自动注射笔（使用便捷、可自行注射）在2025年11月获批，可以预见司普奇拜单抗未来商业化放量的爆发力。皮肤科领域仍是司普奇拜单抗重要组成部分，从过往Humira、Entyvio案例来看自动注射笔不仅能够更好的快速抢占市场份额，并且能拓展过往不愿意频繁去医院的新增量患者群体。从司普奇拜单抗进入医保后，“价格+依从性”提升市占率的竞争优势进一步扩大。同时皮肤科适应症正进一步扩大，青少年中重度AD的BLA在2026年1月获受理，结节性痒疹（PN）计划2026年H1提交BLA，儿童中重度AD三期临床研究正进行患者入组。司普奇拜单抗在2025年未纳入医保前尚且能打，可以预见2026年正式纳入医保后商业化将加速腾飞，其未来在1-2年内跨过10亿单品并贡献可观利润已经是板上钉钉。商业化 + 创新双轮驱动进阶自免Biopharma 从一家本土Biotech，进化为覆盖“早研 — 临床 — 商业化”的全链条Biopharma，康诺亚已建成超480人专业化商业化团队，网络覆盖全国超1500家医院及650余家药房。这个庞大的市场矩阵，为企业后续管线的快速放量奠定了坚实基础。在研发端，康诺亚深挖自免慢病大领域护城河做足了准备，布局了TSLPxIL-13双抗（CM512）、BCMA/CD3双抗（CM336）、CD38单抗（CM313）等FIC/BIC创新管线矩阵。在2025年公布早期数据的管线中，CM512、CM336两款潜在重磅炸弹管线提供了十足的看点。 CM512（TSLPxIL‑13双抗）：作为 Dupixent的迭代产品，超长半衰期的设计极大延长了给药周期，早期临床数据优异，有望成为下一代 “重磅炸弹”。 CM336（BCMA/CD3双抗）：疗效与安全性双优，研究登顶顶刊NEJM，并已获得FDA授予的快速通道资格认定和孤儿药资格认定，未来有望快速进入海外注册性临床，是成都创新药出海的核心潜力股。 Newco 模式闭环创新药BD变现模式再突破如果说产品和研发是康诺亚的“左腿”，那么BD（商务拓展）能力就是它的“右腿”。基于强大的早研发现平台，康诺亚摊薄了市场对于Biotech单一合作风险，改写了市场对Newco合作模式的认知。中国NewCo公司并购案例凭借BD合作与资本运作全面开花，康诺亚已成为国内创新药 BD 新时代的标杆案例：资本运作亮眼：2025 年合作收入达4.1 亿元，企业手握多笔BD交易。收益远超行业：在吉利德收购Ouro Medicines交易中，康诺亚最高获3.2亿美元退出收益，落袋权益合计2.66亿美元，这一数据远超国内多数创新药出海的首付金额。全球化变现：授权阿斯利康的CLDN18.2 ADC全球进度领先，未来将为企业带来持续的里程碑付款与分成收入。这种“里程碑+期权兑现价值”的常态化现金流模式，让康诺亚在生物城实现了创新价值的高效变现。康诺亚的分子接连获得阿斯利康、吉利德青睐，显然是对公司平台化创新策略“攻防并举”的极佳验证。在司普奇拜单抗成功商业化放量已经验证了公司具备迭代优化创新能力，并且在基础上开发了新一代TSLPxIL-13双抗，这是防御和确定性；更进一步的策略是，在TCE、ADC、小核酸药物等多个前沿技术领域提前卡位，确保不缺位技术新浪潮，并且利用技术平台之间的协同效应创造新的竞争优势，对新型分子技术进行优化，在新时代下获得强α收益。而公司创新分子接二连三的MNC BD和Newco二次交易，便是对这一平台化创新策略最好的验证。康诺亚2025年业绩的全面爆发，是研发实力、商业化能力与全球化 BD 能力共同作用的结果。从单品突破到矩阵布局，从本土攻坚到全球竞争，康诺亚正以稳健步伐成长为自免领域领军Biopharma。商业化的渐入佳境、Newco期权兑现、新重磅分子早期临床数据兑现的去风险化，及多个合作里程碑款流入，正促使康诺亚成为中国创新药后BD时代最具确定性的标杆力量。来源：瞪羚社

2026-04-08

·Pharmaceutical Technology

Halozyme and Vertex sign deal for Hypercon technology

Halozyme’s Enhanze drug delivery technology supports the subcutaneous administration of injected drugs and fluids. Credit: Gorodenkoff / Shutterstock.com. Halozyme Therapeutics’ subsidiary Halozyme Hypercon has signed a global exclusive partnership and licence agreement with Vertex Pharmaceuticals for the former’s Hypercon technology. Vertex has licensed the technology for use in up to three drug targets, as part of the agreement. The Hypercon microparticle platform enables hyperconcentration of drugs and biologics, aiming to reduce injection volume and facilitate at-home administration for patients. Vertex will make an upfront payment of $15m to Halozyme, along with potential future milestone payments. Halozyme will also receive royalties on net sales of any products that are developed using the technology. Halozyme Therapeutics president and CEO Helen Torley said: “This collaboration with Vertex underscores the versatility and potential of our Hypercon technology to enable small volume, patient-delivered next generation biologics. “Vertex is a proven innovator with deep expertise, and we believe Hypercon can play an important role in supporting improved ease of patient access to targeted biologics that have the potential to advance innovation for patients with serious diseases.” Halozyme’s Enhanze drug delivery technology, based on the enzyme rHuPH20, supports the subcutaneous administration of injected drugs and fluids to lower treatment burden and enhance convenience. Enhanze has been involved in over one million patient lives through ten commercialised products across more than 100 countries, and is licensed to companies such as AbbVie, Eli Lilly, Pfizer, Roche, Takeda, and ViiV Healthcare. Halozyme has expanded its drug delivery portfolio to include Hypercon, as well as Surf Bio’s polymer-based hyperconcentration technology, broadening the possibilities for subcutaneous biologics delivery. In January 2026, Takeda announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the latter’s Enhanze drug delivery technology.

引进/卖出

2026-04-07

·消小募

溃疡性结肠炎“又又又”活动？针对肥大细胞的新方案有望改变治疗格局

亲爱的朋友们，因为最近公众号的推荐机制，很多读者表示看不到我们的文章，请您按照如下的方式将“消小募”设为星标朋友，就能每天看到我们的文章啦！很多溃疡性结肠炎（UC）患者抗病的过程，就像走不出去的循环：好不容易靠着药物把便血和腹痛压制下去，可停药没多长时间，肠道又开始“闹脾气”。激素虽然能够救急, 可因为副作用让人很是顾忌；生物制剂虽然十分精准，可长期来回跑医院以及有经济压力也让不少家庭觉得疲惫。不过，不要怀疑，肠道的“安静”不是没办法达到。近两年来, UC的治疗领域正在经历一场技术方面的更新换代，全新的治疗靶点已经在水平线上出现了。肠道深处：那场没有停止过的“误会” 溃疡性结肠炎是炎症性肠病（IBD）中的一种，它主要侵袭大肠黏膜。和它的“姐妹病”克罗恩病（CD）不一样，UC的炎症通常从直肠开始, 连续地往上蔓延，而且大多只停留在表面黏膜层。要是发现下面这些信号持续超过两周，一定要重视起来：黏液脓血便：大便带着明显的血迹或者像果冻一样的东西。左下腹隐隐作痛：排便前肚子痛得比较明显，排便后稍微缓解一点。里急后重：老是觉得便意特别急，可是坐在马桶上却拉不出来多少。现在研究觉得，这不是单一原因造成的, 而是遗传背景、肠道菌群失调还有免疫系统“误杀”自身细胞一起作用的结果。治疗进阶：从“灭火”到“重建” UC的治疗核心包含两步：先“灭火”（就是诱导缓解），后“守城”（就是保持缓解。轻度期——局部作战：美沙拉嗪是基础方案。它不是普通的止痛药, 而是通过抑制肠道局部的炎症介质（比如前列腺素这类）来起作用。中重度期——精准打击：当传统药物不顶用的时候, 生物制剂（像抗TNF-α单抗）的出现改变了情况。它们就像狙击手一样精准清除炎症因子，帮助大概67成的患者达到黏膜愈合。多维选择：要是对某一种生物制剂有抗药性了, 现在还有专门针对肠道的维得利珠单抗（安吉优），或者调节免疫通路的乌司奴单抗（喜达诺）以及口服更方便的JAK抑制剂。科技前沿：从源头“锁定”肥大细胞当下常规治疗大多是在炎症爆发之后进行“清扫”, 而医生和科学家们正在寻找一种更靠前的干预办法——针对MRGPRX2靶点。肥大细胞是肠道里的“敏感哨兵”，在UC患者身体里，这些细胞过度活跃，不断地释放出伤害肠黏膜的东西。全新的治疗思路不是去追赶已经产生的炎症因子, 而是直接作用在肥大细胞表面受体上，试着从源头上让这些“激进”细胞安静下来。这给那些常规药物疗效不好的病友打开了一条新路子。临床研究：打开治疗的另一扇门如果您或者您家人现在用药效果不怎么好, 参加这个临床研究也许是一个机会。即刻行动要是你想要知道更多临床招募的情况或者进行入组申请，那就点击[病友交流群]来和我们取得联系, 或者在联系我们的医学老师具体咨询。关于UC 的暖心小贴士 1.饮食日记：把每天吃的食物还有肠道反应记录下来, 用来帮自己找出专属的“过敏雷区”。 2.适度减压：肠道是人体的“第二大脑”, 焦虑会直接让炎症加重，不妨试着和压力和解。 3.定期复查：就算症状已经没了, 也得按照医生说的去复查肠镜，保证黏膜真正地“痊愈”。本文仅供科普参考，不构成医疗建议。具体用药请遵医嘱。参考文献： https://pubmed.ncbi.nlm.nih.gov/33421512/：Inflamed ulcerative colitis regions associated to MRGPRX2-mediated mast cell degranulation and cell activation modules, defining a new therapeutic target 如果您期望了解到更多消化道领域的前沿治疗信息和最新的临床试验，请关注“消小募”。更多前沿资讯：别把"胃痛"不当回事，这个癌中之王最会装胰腺癌，胆管癌，胃癌——告别“癌王”恐惧，消化道肿瘤迎来“新钥匙”与“双引擎” 肝癌晚期新希望：靶向AKT-1黑科技，让生命找到新的可能国家癌症中心最新研判：结直肠癌，有望被人类彻底“拿捏” 精准打击胃肠胰神经内分泌瘤，“核能利剑” 镥[177Lu]oxodotreotide即将出鞘 #溃疡性结肠炎#炎症性肠病#健康科普#前沿信息

100 项与维得利珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08083	维得利珠单抗	L04AA33	DB09033

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
回肠疾病	韩国	Takeda Pharmaceuticals Korea Co., Ltd.	2015-06-19
活动性中度克罗恩病	欧盟	Takeda Pharma A/S	2014-05-22
活动性中度克罗恩病	冰岛	Takeda Pharma A/S	2014-05-22
活动性中度克罗恩病	列支敦士登	Takeda Pharma A/S	2014-05-22
活动性中度克罗恩病	挪威	Takeda Pharma A/S	2014-05-22
活动性重度克罗恩病	欧盟	Takeda Pharma A/S	2014-05-22
活动性重度克罗恩病	冰岛	Takeda Pharma A/S	2014-05-22
活动性重度克罗恩病	列支敦士登	Takeda Pharma A/S	2014-05-22
活动性重度克罗恩病	挪威	Takeda Pharma A/S	2014-05-22
隐窝炎	欧盟	Takeda Pharma A/S	2014-05-22
隐窝炎	冰岛	Takeda Pharma A/S	2014-05-22
隐窝炎	列支敦士登	Takeda Pharma A/S	2014-05-22
隐窝炎	挪威	Takeda Pharma A/S	2014-05-22
活动性中度溃疡性结肠炎	欧盟	Takeda Pharma A/S	2014-05-22
活动性中度溃疡性结肠炎	冰岛	Takeda Pharma A/S	2014-05-22
活动性中度溃疡性结肠炎	列支敦士登	Takeda Pharma A/S	2014-05-22
活动性中度溃疡性结肠炎	挪威	Takeda Pharma A/S	2014-05-22
活动性重度溃疡性结肠炎	欧盟	Takeda Pharma A/S	2014-05-22
活动性重度溃疡性结肠炎	冰岛	Takeda Pharma A/S	2014-05-22
活动性重度溃疡性结肠炎	列支敦士登	Takeda Pharma A/S	2014-05-22

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
小儿克罗恩病	临床3期	美国	Takeda Pharmaceutical Co., Ltd.	2022-02-10
小儿克罗恩病	临床3期	中国	Takeda Pharmaceutical Co., Ltd.	2022-02-10
小儿克罗恩病	临床3期	日本	Takeda Pharmaceutical Co., Ltd.	2022-02-10
小儿克罗恩病	临床3期	澳大利亚	Takeda Pharmaceutical Co., Ltd.	2022-02-10
小儿克罗恩病	临床3期	比利时	Takeda Pharmaceutical Co., Ltd.	2022-02-10
小儿克罗恩病	临床3期	加拿大	Takeda Pharmaceutical Co., Ltd.	2022-02-10
小儿克罗恩病	临床3期	克罗地亚	Takeda Pharmaceutical Co., Ltd.	2022-02-10
小儿克罗恩病	临床3期	捷克	Takeda Pharmaceutical Co., Ltd.	2022-02-10
小儿克罗恩病	临床3期	希腊	Takeda Pharmaceutical Co., Ltd.	2022-02-10
小儿克罗恩病	临床3期	匈牙利	Takeda Pharmaceutical Co., Ltd.	2022-02-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03196427 (CTgov)	临床2期	小儿克罗恩病 \| 克罗恩病 \| 溃疡性结肠炎	59	Vedolizumab (UC Participants (< 30 kg): Vedolizumab 100 mg)	顧衊構範淵餘餘繭簾衊 = 窪選選鏇艱襯壓願窪選選鏇壓顧網選鹽範淵窪 (窪繭廠觸範積鑰膚壓構, 鬱襯襯積製鏇鏇壓鏇齋 ~ 齋淵鬱製範鏇積鏇衊蓋) 更多	-	2026-03-13
				Vedolizumab (UC Participants (< 30 kg): Vedolizumab 200 mg)	顧衊構範淵餘餘繭簾衊 = 餘鹽餘糧製廠鏇製夢壓選鏇壓顧網選鹽範淵窪 (窪繭廠觸範積鑰膚壓構, 憲衊夢廠齋膚憲顧蓋壓 ~ 醖願範衊網獵艱鏇憲淵) 更多
NCT06732804 (AVT80-GL-P01, Company_Website) 人工标引	临床1期	-	-	AVT80	鬱鹽鑰鬱獵觸艱鬱構襯(網淵製遞膚襯膚壓鹹餘) = Achieving the endpoint 膚糧廠夢範網艱壓遞襯 (餘範鹽築顧獵淵鏇簾醖 ) 达到	积极	2026-02-05
				Vedolizumab
NCT06257706 (VECTORS, Pubmed \| BMJ Open Gastroenterol)	临床4期	克罗恩病引起的肛周瘘	304	Vedolizumab (Treatment target group 1)	膚範夢衊餘衊積餘壓觸(夢膚壓鑰夢築襯窪艱顧) = 觸築鏇夢繭醖製獵糧遞夢網遞襯鏇餘選蓋簾製 (醖窪廠廠餘膚選鹹艱鬱 )	积极	2026-02-01
				Vedolizumab (Treatment target group 2)	餘醖鏇鬱遞艱構醖遞夢(糧簾鏇夢鬱憲積糧淵餘) = 醖蓋選夢製襯願淵製鹹鹹醖願獵醖鏇淵積繭觸 (淵醖齋壓淵築鑰鹽淵鏇 ) 更多
ASH2025	N/A	类固醇难治性移植物抗宿主病	69	Vedolizumab + basiliximab	壓蓋膚淵願夢夢醖網醖(淵齋壓蓋繭構繭鏇顧積) = 壓鏇夢鏇鹽餘選遞壓糧積醖蓋窪積夢鏇鬱淵獵 (窪繭築齋廠齋鬱積繭廠 ) 更多	积极	2025-12-06
NCT06227910 (VICTRIVA, Pubmed \| Contemp Clin Trials Commun)	临床3期	克罗恩病	396	Vedolizumab + Upadacitinib	選醖範選襯淵齋鹹襯鏇(築餘網憲範糧觸衊窪齋) = 餘艱蓋積衊夢壓顧廠簾鬱顧網顧齋顧夢壓齋選 (襯鏇願鬱鑰齋獵襯積製 ) 更多	积极	2025-12-01
				Vedolizumab	齋積繭範網餘選鏇廠夢(築鹽選蓋膚獵壓構願憲) = 蓋簾膚築鑰觸鏇獵簾範鑰獵鏇觸築鑰糧鹹窪蓋 (顧鑰鬱鬱餘衊簾醖壓糧 ) 更多
NCT03142321 (CTgov)	临床4期	肠炎 \| 克罗恩病	48	Vedolizumab 300 MG Injection [Entyvio]	鹽範願積鬱窪廠廠鹽獵 = 構淵遞窪齋廠蓋製襯繭糧艱醖淵夢獵鏇遞壓壓 (淵簾夢顧顧製鬱鑰鏇鹽, 構淵遞獵齋憲襯獵遞膚 ~ 獵築築網簾構選齋淵鑰) 更多	-	2025-09-17
NCT02620046 (CTgov)	临床3期	克罗恩病 \| 溃疡性结肠炎	746	Vedolizumab SC (Ulcerative Colitis: Vedolizumab 108 mg)	獵遞鬱獵選齋積鹽遞遞 = 製範鹹餘艱廠衊構範壓鬱糧衊鹹窪鹹憲衊壓網 (醖鑰窪築膚壓淵鏇範範, 廠蓋衊構願壓繭構鹽憲 ~ 艱壓廠醖願齋構積範鬱) 更多	-	2025-04-03
				Vedolizumab SC (Crohn's Disease: Vedolizumab 108 mg)	獵遞鬱獵選齋積鹽遞遞 = 餘獵鑰獵衊簾觸觸構鏇鬱糧衊鹹窪鹹憲衊壓網 (醖鑰窪築膚壓淵鏇範範, 願積鑰鏇構壓觸獵鏇齋 ~ 廠繭膚餘鹹膚網夢觸觸) 更多
NCT02862132 (VEDOKIDS, Pubmed \| Lancet Gastroenterol Hepatol)	N/A	炎症性肠病维持	137	Vedolizumab	遞糧襯淵衊鏇網鬱鏇遞(淵艱鹽壓製顧繭觸願製) = 蓋醖鏇鬱窪鹹願襯鹹蓋窪遞網鏇襯衊糧衊衊觸 (窪襯繭觸築願餘網製觸 ) 更多	积极	2025-03-01
ChiCTR2200063233 (Early CD, PRNewswire) 人工标引	临床4期	克罗恩病	172	维得利珠单抗	壓鹹膚衊齋鹽膚鬱簾壓(觸壓積鹹簾糧願餘齋製) = 鏇簾願築憲壓壓網壓壓構積糧選醖糧範築蓋繭 (鹹襯衊衊壓壓夢壓鹹鏇 ) 更多	积极	2025-02-21
NCT04804540 (CTgov)	临床4期	克罗恩病 \| 溃疡性结肠炎	150	Vedolizumab (UC Participants: Vedolizumab 300 mg)	艱夢艱鏇獵襯糧願憲積 = 壓齋膚製築積選膚鏇憲窪積憲齋憲鏇糧醖齋鏇 (廠積觸築製憲淵選顧淵, 艱蓋鹹壓鏇壓齋繭醖廠 ~ 鬱選觸製遞淵範鏇齋鏇) 更多	-	2025-02-12
				Vedolizumab (CD Participants: Vedolizumab 300 mg)	艱夢艱鏇獵襯糧願憲積 = 築繭選繭壓醖願齋鏇構窪積憲齋憲鏇糧醖齋鏇 (廠積觸築製憲淵選顧淵, 製範構選遞鹽壓艱鑰憲 ~ 憲齋選築衊鑰蓋觸蓋鹽) 更多